BiomX (PHGE) Stock Price, News & Analysis

Company Overview

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Key Stats

• Today's Range: $0.72 to $0.78
• 50-Day Range: $0.50 to $0.63
• 52-Week Range: $0.48 to $4.90
• Volume: 53,300 shs
• Average Volume: 81,532 shs
• Market Capitalization: $13.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

BiomX Stock Analysis - MarketRank™

BiomX scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BiomX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BiomX are expected to grow in the coming year, from ($0.44) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BiomX is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BiomX is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BiomX has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PHGE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BiomX does not currently pay a dividend.

Dividend Growth

BiomX does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for PHGE.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

BiomX has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BiomX this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BiomX insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.17% of the stock of BiomX is held by insiders.

Percentage Held by Institutions

40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHGE Stock Analysis - Frequently Asked Questions

How have PHGE shares performed this year?

BiomX's stock was trading at $0.7301 at the start of the year. Since then, PHGE stock has decreased by 31.8% and is now trading at $0.4980.
View the best growth stocks for 2025 here.

How were BiomX's earnings last quarter?

BiomX Inc. (NYSEMKT:PHGE) announced its quarterly earnings data on Monday, May, 15th. The company reported ($2.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.80) by $0.20.

When did BiomX's stock split?

Shares of BiomX reverse split on Monday, August 26th 2024. The 1-10 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are BiomX's major shareholders?

BiomX's top institutional shareholders include Nantahala Capital Management LLC (9.97%), Alyeska Investment Group L.P. (6.36%), AIGH Capital Management LLC (6.27%) and Allostery Investments LP (3.76%). Insiders that own company stock include Israel Biofund Gp Limi Orbimed, Chidozie Ugwumba and Assaf Oron.
View institutional ownership trends.

How do I buy shares of BiomX?

Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BiomX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), NVIDIA (NVDA), Zomedica (ZOM), Insulet (PODD) and Ford Motor (F).

Company Calendar

• Last Earnings: 5/15/2023
• Today: 5/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEMKT
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEMKT:PHGE
• CIK: 1739174
• Web: www.biomx.com
• Phone: 972 7 23942377
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +3,985.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -127.82%
• Return on Assets: -56.50%

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 2.84
• Quick Ratio: 2.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.70 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 26,176,000
• Free Float: 44,044,000
• Market Cap: $13.45 million
• Optionable: Not Optionable
• Beta: 1.51